NEW YORK, September 6, 2017 /PRNewswire/ --
If you want a Stock Review on PKI, BEAT, BRKR, or ONVO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. In today's pre-market research, DailyStockTracker.com covers the performances of the following equities: PerkinElmer Inc. (NYSE: PKI), BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), and Organovo Holdings Inc. (NASDAQ: ONVO). These companies belong to the Medical Laboratories space, which includes independent, commercial enterprises that provide information to healthcare professionals about the severity, onset, and reason of patients' physical ailments. Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at:
On Tuesday, shares in Waltham, Massachusetts headquartered PerkinElmer Inc. recorded a trading volume of 554,142 shares. The stock ended the session 0.31% higher at $67.20. The Company's shares have gained 4.53% in the last one month, 3.78% over the previous three months, and 28.86% on an YTD basis. The stock is trading 0.77% above its 50-day moving average and 13.53% above its 200-day moving average. Moreover, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have a Relative Strength Index (RSI) of 62.18.
On August 28th, 2017, PerkinElmer announced that the Company will present at the 15th annual Morgan Stanley Global Healthcare Conference on September 11th, 2017 at 11:40 a.m. ET at the Grand Hyatt New York. Robert Friel, Chairman and CEO, will provide an overview of the Company and its strategic objectives. A live audio webcast of the presentation will be available under the Investors section of the Company's website. The free research report on PKI is available at:
Malvern, Pennsylvania headquartered BioTelemetry Inc.'s stock closed the day 0.40% higher at $37.75 with a total trading volume of 257,335 shares. The Company's shares have advanced 11.19% in the past month, 32.92% in the previous three months, and 68.90% since the start of this year. The stock is trading 9.79% and 35.05% above its 50-day and 200-day moving averages, respectively. Additionally, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 65.13.
On August 08th, 2017, BioTelemetry reported results for Q2 ended June 30th, 2017. For the quarter, revenue was $58.1 million; net income was $1.7 million; adjusted net income was $7.4 million; and adjusted EBITDA was $14.0 million. The Company also increased its full year 2017 revenue guidance to $285 million to $290 million, with expected adjusted EBITDA of approximately 23% of revenue.
On August 09th, 2017, research firm Dougherty & Company reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $37 a share to $40 a share. The complimentary report on BEAT can be downloaded at:
Billerica, Massachusetts headquartered Bruker Corp.'s stock recorded a trading volume of 495,235 shares, and ended yesterday's trading session 0.65% lower at $28.92. The Company's shares have advanced 3.73% in the past month, 5.59% in the previous three months, and 36.54% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.45% and 15.30%, respectively. Furthermore, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 57.43.
On August 14th, 2017, Bruker announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock. The dividend will be paid on September 22nd, 2017 to stockholders of record as of September 05th, 2017. Visit us today and download our complete research report on BRKR for free at:
San Diego, California headquartered Organovo Holdings Inc.'s ("ONVO") stock finished Tuesday's session 0.98% higher at $2.07 with a total trading volume of 764,099 shares. The Company's shares are trading below their 50-day moving average by 10.29%. Shares of the Company, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have an RSI of 46.83.
On August 23rd, 2017, ONVO announced that it has awarded the 2017 ExVive 3D Tissue Application Award to researchers at Amgen, Inc. and Medikine, Inc. The program is designed to explore new applications using ONVO's ExVive Liver and Kidney Tissues in collaboration with biopharmaceutical partners. The Company had many applicants for its awards, with the winners submitting the two most creative and novel proposals with the aim of bridging preclinical and clinical research. Get free access to your technical report on ONVO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.